Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Pharma Industry / Biotech Industry News

GSK To Offer Flexible Drug Pricing In Middle-Income Countries

Main Category: Pharma Industry / Biotech Industry
Article Date: 11 Mar 2010 - 6:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Drug maker GlaxoSmithKline (GSK) "plans to bolster earnings by selling to more people in middle-income countries after cutting prices in the world's poorest nations," Bloomberg/BusinessWeek reports.

"Our strategy is to grow our business in middle-income countries by increasing the volume of products we sell," GSK Chief Executive Andrew Witty said by e-mail, according to the news service. "Extending [GSK's] flexible pricing program for such nations would 'improve the affordability of our medicines, increase access for patients with lower income levels and be profitable for GSK,' he said."

Middle-income countries vary "in terms of economic status, demography and health-care infrastructure which can vary significantly," Witty explained, the news service continues. "Taking a single pricing approach would be difficult, inappropriate and inequitable," he added. The news service notes Witty did not name individual countries (Ghosh, 3/9).

The Hindu Business Line reports on GSK's rationale for the customized approach to pricing for middle-income countries (Datta, 3/9).

"The long-term purpose of the initiative is to make its medicines accessible to all income groups," Economic Times/India Times reports. "The strategy will be executed through a combination of alliances with local firms or reduction of prices of selective brands," according to the news paper (Singh/Kumar, 3/10). Economic Times/India Times also features an interview with Witty (Singh/Kumar, 3/10).

In related news, Witty was in Nashik, India, on Monday to dedicate a new factory that will produce "albendazole, part of a combination treatment used within the World Health Organization's (WHO) Global Programme to Eliminate Lymphatic Filariasis (LF)," according to a GSK press release. The new facility "is expected to deliver 300 million tablets" of albendazole this year, the press release notes (3/8).

This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org.

© Henry J. Kaiser Family Foundation. All rights reserved.







Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Monthly Feature

Drowning Image
Drowning Doesn't Look Like You May Think It Does...

If you are heading to the water this summer, ask yourself this question - would you be able to spot someone in trouble in the water, in time to save their life? Read our article here...

Forum Icon

Pharma Industry Forum

Discuss issues relating to pharma industry / biotech industry in our new forum.

Visit the pharma industry forum


These are the most read articles from this news category for the last 6 months:
Top Article Star
Lupus Drug Benlysta® (belimumab) Priority Review Granted By FDA
20 Aug 2010
Benlysta® (belimumab), a potential treatment for systemic lupus erythematosus has been granted a priority review designation by the FDA (Food and Drug Administration, USA), which is granted to medications, that if...


Follow Our News On Twitter:
Pharma Industry

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply click the link below and select the 'follow' option.